BIOCYTOGEN-B (02315) rose more than 6% during the morning session, reaching a high of HK$37.28 and setting a new record high since its listing. As of the writing of this report, the stock was up 5.99% to HK$37.18, with a turnover of HK$78.7927 million. The catalyst for the move was a recent announcement by the Shanghai and Shenzhen stock exchanges that BIOCYTOGEN-B will be included in the Hong Kong Stock Connect list, effective December 24, 2025. The company stated that this successful inclusion marks another significant milestone in its capital market development following the establishment of its dual A+H listing platform, signaling a new phase for the company in terms of capital accessibility, market recognition, and long-term investment value. Galaxy Securities released a research report stating that BIOCYTOGEN, with its foundation in gene editing technology, is poised for substantial earnings growth as its major investment, the "10,000-Antibody" initiative, enters a phase of delivering results. The report pointed out that after the company's listing on the STAR Market, it formed a dual A+H capital structure, with the A-shares offering superior liquidity; the Hong Kong shares, as the primary listing platform, were included in the Hong Kong Stock Connect on December 24, 2025, and currently trade at a significant valuation discount, providing a higher margin of safety.
Comments